Agios expects to advance cevidoplenib into Phase 3 for ITP in H1 2028
Company plans to start Phase 2/3 development of AG-236 for polycythemia vera in H2 2026
Agios expects current cash and revenue to fund launches and pipeline advancement
Result drivers
U.S. launch of AQVESME - Revenue growth was driven by the U.S. commercial launch of AQVESME (mitapivat) in thalassemia
European approval - Ex-U.S. revenue reflected demand for PYRUKYND (mitapivat) in Europe after approval for thalassemia
Higher operating expenses - R&D and SG&A expenses increased due to licensing costs and commercial launch activities
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $46.00, about 31.4% above its July 29 closing price of $35.01
AGIO•
